In patients without atopic dermatitis, anti‐IL5 biologics were the first‐line treatment in 59% of cases, whereas they were only prescribed as the first‐line treatment in 35% of patients with comorbid atopic dermatitis. The gene discussed is IL5; the disease is atopic eczema.